All In Biotech

Drug Trial Radar · NCT03847909

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria

Last checked: Nov 20, 2026Latest source record: May 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

35

Actual

Start

Oct 28, 2019

Primary completion

Jun 21, 2021

Study completion Jun 29, 2021

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Feb 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of DCR-PHXC in Children and Adults with Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2)

Conditions

  • Primary Hyperoxaluria Type 1 (PH1)
  • Primary Hyperoxaluria Type 2 (PH2)
  • Kidney Diseases
  • Urologic Diseases
  • Genetic Disease

Interventions

  • DCR-PHXCDrug

    Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection

  • Sterile Normal Saline (0.9% NaCl)Drug

    Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC From Day 90 To Day 180, Based on Percent Change From Baseline in 24-Hour UoxTime frame: From Day 90 to 180

Locations

28 sites in 15 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    San Francisco, California

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Pittsburgh, Pennsylvania

  • Clinical Trial Site

    Herston, Australia

  • Clinical Trial Site

    Parkville, Australia

  • Clinical Trial Site

    Hamilton, Canada

  • Clinical Trial Site

    Bron, France

  • Clinical Trial Site

    Paris, France

  • Clinical Trial Site

    Bonn, Germany

  • Clinical Trial Site

    Heidelberg, Germany

  • Clinical Trial Site

    Jerusalem, Israel

  • Clinical Trial Site

    Roma, Italy

  • Clinical Trial Site

    Nagoya, Japan

  • Clinical Trial Site

    Tochigi, Japan

  • Clinical Trial Site

    Tokyo, Japan

  • Clinical Trial Site

    Beirut, Lebanon

  • Clinical Trial Site

    Beirut, Lebanon

  • Clinical Trial Site

    Amsterdam, Netherlands

  • Clinical Trial Site

    Auckland, New Zealand

  • Clinical Trial Site

    Bialystok, Poland

  • Clinical Trial Site

    Bucharest, Romania

  • Clinical Trial Site

    Barcelona, Spain

  • Clinical Trial Site

    Santa Cruz, Spain

  • Clinical Trial Site

    Birmingham, United Kingdom

  • Clinical Trial Site

    London, United Kingdom

  • Clinical Trial Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.